- This event has passed.
HE@Cam: Peter Morten – New therapies, new methods: the use of novel survival analysis methods for I-O therapies – Peter Morten – Costello Medical
5 November 2018, 3:00 pm-4:00 pm
Health Economics at Cambridge (HE@Cam) are pleased to present Peter Morten, Costello Medical, for a seminar on Immuno-oncology (I-O) therapies. This novel approach to fighting certain types of cancer has been clinically effective, but also poses a new set of challenges for those trying to assess its effectiveness. In his talk, Peter will discuss early approaches to survival modelling with I-O therapies in the UK, and the methodological demands of future health technology assessment.
Information can also be found “here”:http://www.publichealth.cam.ac.uk/seminar-05-nov-2018-peter-morten/
*Time:* 15:00-16:00 Monday 5th November 2018
*Venue:* Large seminar room, Institute of Public Health, Cambridge
*All Welcome. Part of HE@Cam seminar 2018/19 series.*
*About the seminar:*
Immuno-oncology (I-O) therapies have emerged in the last few years as promising cancer treatments. These therapies present a novel mechanism of action – essentially removing the “brakes” placed on the body’s immune system by tumours – and have proven clinically effective across an ever-growing range of tumour types.
The survival profiles for patient populations treated with these I-O therapies have shown emerging evidence of notable features, including a plateau in the overall survival curve and evidence of a delayed clinical effect. Based on this, standard parametric distributions, which are recommended by the NICE Decision Support Unit, may not be adequate to model these complex survival functions over the long term. As such, recent health technology assessments (HTAs) have seen the application by manufacturers of alternative approaches to modelling survival with I-O therapies, including mixture cure models and response-based models.
This talk will present a review of the use and acceptance (or lack thereof) of alternative survival modelling approaches for I-O therapies in UK HTA. The challenges and barriers to acceptance of these methods by decision-makers will be discussed, alongside perspectives on potential developments in this area in the near future.
Peter is a Consultant in the HTA and Health Economics division at Costello Medical, a medical communications and health economics consultancy founded in Cambridge and now based in Cambridge, London and Singapore. Peter’s role involves leading the development of pharmaceutical companies’ written submissions of evidence to HTA bodies like NICE in England and Wales and the SMC in Scotland, as well as the development of the health economic models that provide the evidence around cost-effectiveness for these submissions. Peter has worked in the field of HTA for I-O therapies for the last two years; hence the inspiration for his interest in this area.